Background: We report on a double‐blind, crossover pilot trial for the treatment of rapid eye
movement behavior disorder (RBD) in 12 patients with Parkinson's disease in whom …

We aimed to determine prospectively whether rivastigmine, an inhibitor of
acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and …

Rapid eye movement (REM) sleep behavior disorder (RBD) involves complex behavior and
a loss of muscle atonia occuring during REM sleep. Half of these patients with RBD have an …

In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety
of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were …

This open study assessed the ability of rivastigmine to treat the neuropsychiatric
complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations …

We read with interest the article by Mohr and colleagues1 on risperidone treatment of
psychosis in Parkinson's disease (PD). We wish to address the notion that risperidone may …

Autonomic failure+++++++++++++++ Cerebellar signs++ 0+++++++ 0+ Cognitive
dysfunction++++++++++++++++++++ Dysarthria+++++++++++++++++++ …

The purpose of this study was to assess whether rivastigmine, a cholinergic agent, affects
tremor features when given to improve cognition in demented Parkinson's disease (PD) …

The objective of this study was to investigate how acetylcholinesterase inhibitor (ChEI)
treatment affects brain function in Parkinson's disease (PD). Twelve patients with PD and …

Background Rapid eye movement (REM) sleep behavior disorder (RBD) is present in
around 40% of Parkinson's disease (PD) patients. Definitive diagnosis requires a …